$94.6 Million is the total value of Stonepine Capital Management, LLC's 27 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 78.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LGND | New | LIGAND PHARMACEUTICALS | $11,702,000 | – | 160,919 | +100.0% | 12.38% | – |
| ISEE | Sell | IVERIC BIO INC | $8,888,000 | -65.5% | 2,583,786 | -13.9% | 9.40% | -47.6% |
| CTIC | Buy | CTI BIOPHARMA CORP | $5,916,000 | -0.3% | 6,430,637 | +71.3% | 6.26% | +51.3% |
| AMRN | Sell | AMARIN CORP PLC -ADRspons adr new | $5,252,000 | -84.2% | 1,313,100 | -15.4% | 5.55% | -76.0% |
| AFMD | Sell | AFFIMED NV | $4,740,000 | -56.9% | 3,000,000 | -25.2% | 5.01% | -34.5% |
| CBIO | Buy | CATALYST BIOSCIENCES INC | $4,454,000 | +112.8% | 1,019,196 | +231.7% | 4.71% | +222.8% |
| STML | New | STEMLINE THERAPEUTICS INC | $4,291,000 | – | 886,632 | +100.0% | 4.54% | – |
| XOMA | Buy | XOMA CORP | $4,245,000 | -22.5% | 208,600 | +4.0% | 4.49% | +17.5% |
| OPNT | Buy | OPIANT PHARMACEUTICALS INC | $3,649,000 | -24.2% | 380,948 | +14.0% | 3.86% | +15.0% |
| NEOS | Sell | NEOS THERAPEUTICS INC | $3,518,000 | -52.1% | 4,690,146 | -3.5% | 3.72% | -27.2% |
| OXFD | Sell | OXFORD IMMUNOTEC GLOBAL PLC | $3,467,000 | -66.9% | 374,431 | -40.6% | 3.67% | -49.8% |
| EOLS | Buy | EVOLUS INC | $3,415,000 | -28.9% | 822,960 | +108.4% | 3.61% | +7.8% |
| ADMS | Sell | ADAMAS PHARMACEUTICALS INC | $3,361,000 | -60.4% | 1,162,876 | -48.1% | 3.55% | -40.0% |
| CPIX | Buy | CUMBERLAND PHARMACEUTICALS | $3,295,000 | -28.6% | 907,735 | +1.3% | 3.48% | +8.3% |
| APEN | Buy | APOLLO ENDOSURGERY INC | $3,233,000 | -31.3% | 1,683,861 | +2.0% | 3.42% | +4.2% |
| CDTX | New | CIDARA THERAPEUTICS INC | $3,231,000 | – | 1,302,981 | +100.0% | 3.42% | – |
| New | AEGERION PHARMACEUTICALSAEGR 5 04/01/25note 5.000% 4/0 | $2,886,000 | – | 3,037,627 | +100.0% | 3.05% | – | |
| BDSI | New | BIODELIVERY SCIENCES INTL | $2,861,000 | – | 755,000 | +100.0% | 3.03% | – |
| CHMA | Buy | CHIASMA INC | $2,716,000 | +198.1% | 744,134 | +305.2% | 2.87% | +352.3% |
| DMAC | New | DIAMEDICA THERAPEUTICS INC | $2,311,000 | – | 825,297 | +100.0% | 2.44% | – |
| SPNE | New | SEASPINE HOLDINGS CORP | $2,068,000 | – | 253,131 | +100.0% | 2.19% | – |
| AGTC | New | APPLIED GENETIC TECHNOLOGIES | $1,925,000 | – | 586,969 | +100.0% | 2.04% | – |
| BXRX | New | BAUDAX BIO INC | $1,513,000 | – | 610,200 | +100.0% | 1.60% | – |
| Sell | INTERPACE BIOSCIENCES INC | $924,000 | +95.8% | 178,295 | -81.1% | 0.98% | +197.0% | |
| ATRS | New | ANTARES PHARMA INC | $357,000 | – | 151,189 | +100.0% | 0.38% | – |
| HTGM | Sell | HTG MOLECULAR DIAGNOSTICS | $323,000 | -90.3% | 992,641 | -79.1% | 0.34% | -85.3% |
| RIGL | New | RIGEL PHARMACEUTICALS INC | $16,000 | – | 10,000 | +100.0% | 0.02% | – |
| ACER | Exit | ACER THERAPEUTICS INC | $0 | – | -20,000 | -100.0% | -0.06% | – |
| TORC | Exit | RESTORBIO INC | $0 | – | -81,772 | -100.0% | -0.08% | – |
| SCYX | Exit | SCYNEXIS INC | $0 | – | -609,384 | -100.0% | -0.39% | – |
| SBBP | Exit | STRONGBRIDGE BIOPHARMA PLC | $0 | – | -431,853 | -100.0% | -0.63% | – |
| APVO | Exit | APTEVO THERAPEUTICS INC | $0 | – | -4,179,131 | -100.0% | -1.91% | – |
| NVLNF | Exit | NOVELION THERAPEUTICS INC | $0 | – | -3,909,207 | -100.0% | -1.92% | – |
| Exit | AEGERION PHARMACEUTICALS INCnote 5.000% 4/0 | $0 | – | -2,993,334 | -100.0% | -1.98% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.